Analyst Insights: Express Scripts, Cavium Networks, Array BioPharma, Keryx Biopharmaceuticals April 3rd

Express Scripts Inc. (NASDAQ:ESRX): Cowen said the merger between Express Scripts (NASDAQ:ESRX) and Medco Health (NYSE:MHS) was timely and should generate better than expected synergies. The firm cited the lack of divestitures as a positive although indicates a competitive landscape which they believe will be navigated efficiently. Shares of Express Scripts are rated Outperform.

Cavium Networks, Inc. (NASDAQ:CAVM): Needham said its investment thesis for Cavium Networks is unchanged after the company lowered its outlook for Q1. The firm does not believe Cavium lost market share and maintains a Buy rating on the stock.

Array BioPharma, Inc. (NASDAQ:ARRY): Leerink raised its price target for Array Biopharma after the company’s MEK inhibitor selumetinib showed activity in low-grade serous ovarian cancer patients. The firm keeps a Market Perform rating on the stock.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX): Stifel Nicolaus reduced its target on Keryx after the company announced that capecitabine perifosine failed to meet the primary endpoint in a trial. The firm thinks the miss significantly reduces visibility into the ongoing P3 multiple myeloma trial, and it removed all perifosine revenue from its estimates. However, the firm maintains a Buy rating on Keryx.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.